Estrella Immunopharma Inc (ESLA)

$1.18 -0.01 (-0.84%)
Market Cap 44.94M
Revenue (ttm) 0.00
Net Income (ttm) -7.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 33,400
Avg Vol 210,336
Day's Range N/A - N/A
Shares Out 37.77M
Stochastic %K 55%
Beta 0.55
Analysts Strong Sell
Price Target $8.00

Company Profile

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 318 9098
Address:
5858 Horton Street, Suite 370, EmeryVille, United States
BillionerOfKing
BillionerOfKing Feb. 22 at 10:22 PM
$ESLA Current Stock Price: $1.18
0 · Reply
CandleTactix
CandleTactix Feb. 17 at 9:18 AM
$ESLA Obscure micro-cap; likely a shell
0 · Reply
Pb1782
Pb1782 Feb. 13 at 3:43 PM
$ESLA
0 · Reply
GammaForager
GammaForager Feb. 10 at 2:58 PM
$ESLA is a esla or energy company; name suggests clean energy, a competitive sector.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 4:21 AM
$ESLA Current Stock Price: $1.42
0 · Reply
ZacksSCR
ZacksSCR Feb. 9 at 7:04 PM
$ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL https://buff.ly/zdOT8JR
0 · Reply
neangewo
neangewo Feb. 9 at 12:40 PM
$ESLA PR is out and the headline could not be any better! Will the price run up though? We shall see.
0 · Reply
neangewo
neangewo Feb. 9 at 1:54 AM
$ESLA PR AM tomorrow?
0 · Reply
Guerreraa
Guerreraa Feb. 8 at 7:38 PM
$ESLA
0 · Reply
BonjerminFranklin
BonjerminFranklin Feb. 6 at 10:01 PM
$ESLA wtf!? 😂
1 · Reply
Latest News on ESLA
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Feb 9, 2026, 7:00 AM EST - 17 days ago

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Feb 3, 2026, 8:00 AM EST - 23 days ago

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Jan 6, 2026, 2:02 PM EST - 7 weeks ago

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Jan 5, 2026, 8:30 AM EST - 7 weeks ago

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Dec 4, 2025, 8:00 AM EST - 3 months ago

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Nov 3, 2025, 8:00 AM EST - 4 months ago

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Oct 6, 2025, 8:00 AM EDT - 5 months ago

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Jun 3, 2025, 8:00 AM EDT - 9 months ago

Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

May 29, 2025, 8:01 AM EDT - 9 months ago

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Mar 5, 2025, 8:00 AM EST - 1 year ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Feb 21, 2025, 8:30 AM EST - 1 year ago

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Feb 19, 2025, 4:46 PM EST - 1 year ago

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Sep 27, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

Aug 14, 2024, 12:00 PM EDT - 1 year ago

Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Sep 29, 2023, 10:34 AM EDT - 2 years ago

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Estrella Immunopharma Nears Completion Of SPAC Listing

Sep 19, 2023, 1:30 AM EDT - 2 years ago

Estrella Immunopharma Nears Completion Of SPAC Listing

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Sep 18, 2023, 5:00 PM EDT - 2 years ago

TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

Oct 3, 2022, 7:27 AM EDT - 3 years ago

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

BillionerOfKing
BillionerOfKing Feb. 22 at 10:22 PM
$ESLA Current Stock Price: $1.18
0 · Reply
CandleTactix
CandleTactix Feb. 17 at 9:18 AM
$ESLA Obscure micro-cap; likely a shell
0 · Reply
Pb1782
Pb1782 Feb. 13 at 3:43 PM
$ESLA
0 · Reply
GammaForager
GammaForager Feb. 10 at 2:58 PM
$ESLA is a esla or energy company; name suggests clean energy, a competitive sector.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 10 at 4:21 AM
$ESLA Current Stock Price: $1.42
0 · Reply
ZacksSCR
ZacksSCR Feb. 9 at 7:04 PM
$ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL https://buff.ly/zdOT8JR
0 · Reply
neangewo
neangewo Feb. 9 at 12:40 PM
$ESLA PR is out and the headline could not be any better! Will the price run up though? We shall see.
0 · Reply
neangewo
neangewo Feb. 9 at 1:54 AM
$ESLA PR AM tomorrow?
0 · Reply
Guerreraa
Guerreraa Feb. 8 at 7:38 PM
$ESLA
0 · Reply
BonjerminFranklin
BonjerminFranklin Feb. 6 at 10:01 PM
$ESLA wtf!? 😂
1 · Reply
stinstewart
stinstewart Feb. 6 at 7:17 PM
$ESLA big volume
0 · Reply
stinstewart
stinstewart Feb. 6 at 7:16 PM
$ESLA news already out? Nasdaq: ESLA today announced its STARLIGHT-1 phase I result will be orally presented at the 2026 ASTCT & CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood & Marrow Transplant Research). The presentation will highlight clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). Estrella’s late-breaking abstract will be available on February 4, 2026, at 12:00 a.m. CT, via the conference website at www.tandemmeetings.com. Details of the Late-Breaking Oral Presentation: · Final Paper Number: LBA-1 · Abstract ID & Title: 29644: Phase-1 Study of CD19-ARTEMIS T Cells (EB103) in Patients with Aggressive B-Cell · Session Date/Time: Saturday, February 7, 2026, 3:15 p.m. MST · Presenting Author: Naseem Esteghamat, MD MS
0 · Reply
neangewo
neangewo Feb. 6 at 4:49 PM
$ESLA So much for positive momentum before their late breaker presentation tomorrow!
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 6 at 4:40 PM
$ESLA RSI: 50.48, MACD: -0.0822 Vol: 0.10, MA20: 1.05, MA50: 1.43 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BonjerminFranklin
BonjerminFranklin Feb. 6 at 4:24 PM
$ESLA closing under $1! .. stack up, rinse and repeat!
0 · Reply
BonjerminFranklin
BonjerminFranklin Feb. 6 at 3:36 PM
$ESLA under $1 back we go!
0 · Reply
StockScanners
StockScanners Feb. 6 at 5:50 AM
$ESLA keep watch if this holds above 1.10
0 · Reply
topstockalerts
topstockalerts Feb. 5 at 8:48 PM
$ESLA not bad today.. 🙌
0 · Reply
rightsense
rightsense Feb. 5 at 8:36 PM
$TEAD $LIMN $TRUG $GDTC $ESLA or an offering
0 · Reply
IIStock_LesnarII
IIStock_LesnarII Feb. 5 at 8:35 PM
$TEAD $LIMN $TRUG $GDTC $ESLA TEAD — Google Partnership News Float locked Can run up from here and into after hours Let’s make up for this weak market today LFG
0 · Reply
topstockalerts
topstockalerts Feb. 5 at 8:20 PM
$ESLA Following this closely as it continues to build momentum. Buyers are in control. Could be more upside ahead.
0 · Reply
Digitalization2026
Digitalization2026 Feb. 5 at 8:09 PM
Top Gainers PT2 $ESLA $PSNY $MSDD $TRUG Eyes on 🚀 BTOG – Momentum Could Hit Any Day Bit Origin is grinding toward $3, ultra-low float (~1.5M shares) + thin tape = perfect setup. Once momentum hits, any day, anytime between now and the next couple of weeks, this could surge toward possible 52-week highs. 📌 Catalysts: • DOGE treasury updates & capital deployment • SEC/quarterly filings • Crypto market moves (DOGE/BTC) • Funding or facility news 📈 Speculative Price Targets: $3.50–$5 → $7–$10+ → $12+ 🔥 Thin tape + low float + catalysts + trapped shorts = explosive upside. Watch for the break.
0 · Reply